Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Canevari

Showing results (91-100 of 131) with videos related to

Pageof 14
Sort By:
Cancer Immunology, Immunotherapy : CII|March 22, 2001
Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2F Turatti, D Mezzanzanica, E Nardini, et al.
International Journal of Cancer|May 28, 1992
Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cellsS Miotti, S Alberti, P Facheris, et al.
Clinical & Experimental Metastasis|July 20, 1999
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitroV Dolo, S D'Ascenzo, S Violini, et al.
International Journal of Cancer|September 2, 1999
Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigensK A Smans, M B Ingvarsson, P Lindgren, et al.
Cytokine|August 18, 2001
Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumoursD R Negri, D Mezzanzanica, S Sacco, et al.
Journal of Hematotherapy|October 1, 1995
Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directionsS Canevari, D Mezzanzanica, A Mazzoni, et al.
European Journal of Biochemistry|January 2, 1989
The Aspergillus toxin restriction is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cellsF P Conde, R Orlandi, S Canevari, et al.
Cancer Research|December 29, 1998
IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastasesM Rodolfo, C Melani, C Zilocchi, et al.
International Journal of Cancer|September 4, 1995
Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude miceE Tosi, O Valota, D R Negri, et al.
International Journal of Cancer|February 13, 1999
Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survivalS Miotti, D R Negri, O Valota, et al.
Pageof 14

Showing results (91-100 of 131) with videos related to

Sort By:
Pageof 14
Cancer Immunology, Immunotherapy : CII|March 22, 2001
Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2F Turatti, D Mezzanzanica, E Nardini, et al.
International Journal of Cancer|May 28, 1992
Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cellsS Miotti, S Alberti, P Facheris, et al.
Clinical & Experimental Metastasis|July 20, 1999
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitroV Dolo, S D'Ascenzo, S Violini, et al.
International Journal of Cancer|September 2, 1999
Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigensK A Smans, M B Ingvarsson, P Lindgren, et al.
Cytokine|August 18, 2001
Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumoursD R Negri, D Mezzanzanica, S Sacco, et al.
Journal of Hematotherapy|October 1, 1995
Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directionsS Canevari, D Mezzanzanica, A Mazzoni, et al.
European Journal of Biochemistry|January 2, 1989
The Aspergillus toxin restriction is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cellsF P Conde, R Orlandi, S Canevari, et al.
Cancer Research|December 29, 1998
IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastasesM Rodolfo, C Melani, C Zilocchi, et al.
International Journal of Cancer|September 4, 1995
Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude miceE Tosi, O Valota, D R Negri, et al.
International Journal of Cancer|February 13, 1999
Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survivalS Miotti, D R Negri, O Valota, et al.
Pageof 14